RepliCel Life Sciences Inc. announced the granting and/or allowance of seven patent applications since December 2020. The two patent families involved are REPL 403 related in the RepliCel dermal injector and REPL 407 related to compositions and methods for treating and repairing tendons. Specifically, with respect to Dermal Injection Device (RCI-02), company have recently been granted one patent in China, and received notices of allowance on three patent applications (in the United States, Japan and Israel). With respect to program for Chronic Achilles Tendinopathy (RCT-01), company have also received notices of allowances on three patent applications.